Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Cancer suppressor p53 is mutated in more than 50% of human cancers of different origin, while its pathway is altered in about 80% of tumors. This study suggests a therapeutic strategy as to how p53-deficient or mutant p53 expressing human cancers can be cured by activating its “homologous protein such as TAp63”
1α, 25-dihydroxyvitamin D3 (Calcitriol), by increasing the expression of its target genes, it may increase the expression of tumor suppressor TAp63. Thereby, it may inhibit the migration and invasion of metastatic cancer cells. Thus, pharmacological formulations encompassing ” Calcitriol or its analogues” may be used to inhibit the progression of invasive tumors.
Given that exposure to Sunlight increases (1) the levels of 1,25-dihydroxyvitamin D; and (2) the expression of TAp63, one may expose to the optimal level of sunlight to stall metastatic cancer progression. Taken together, this study suggests, for the first time, a vitamin-based therapy for p53-mutated metastatic human tumors.
Undisclosed information: How Calcitriol increases the expression of TAp63
Citation: Boominathan, L., Sunlight exposure stalls p53-mutated metastatic cancer progression: Calcitriol (1α, 25-dihydroxyvitamin D3) increases the expression of tumor suppressor p53 homolouge TAp63 and inhibits migration and invasion of metastatic cancer cells via down regulation of its target gene, 19/April/2015, 10.423am, Genome-2-Bio-Medicine Discovery center (GBMD)
Courtesy: When you cite drop us a line at firstname.lastname@example.org
# Research cooperation